The Dr. Tyna Show

The Fight for Affordable GLP1s & the Truth About Big Pharma | Dave Knapp

Mar 27, 2025
Dave Knapp, an independent journalist and community leader, shares his compelling journey with obesity and type 2 diabetes while exploring GLP-1 receptor agonists. He discusses the FDA’s crackdown on compounding pharmacies and its implications for access to these vital medications. Knapp reveals how Pharmacy Benefit Managers manipulate drug prices, making health access more difficult. Additionally, he challenges traditional weight loss methods and highlights the urgency of addressing metabolic health issues in our communities.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

GLP-1s and Metabolic Health

  • GLP-1 medications mimic hormonal changes after bariatric surgery.
  • They help level the metabolic playing field, improving overall health.
INSIGHT

Compounding Pharmacies and Shortages

  • Compounding pharmacies (503A & 503B) play a role in drug accessibility, especially during shortages.
  • The 2013 Drug Quality and Security Act established 503B pharmacies to address drug shortages by allowing mass production.
INSIGHT

Wegovy's True Cost

  • Most people with insurance pay less than $25 for Wegovy.
  • The list price doesn't reflect the actual cost due to Pharmacy Benefit Managers (PBMs).
Get the Snipd Podcast app to discover more snips from this episode
Get the app